Therapy-related myeloid neoplasms (t-MNs) are a complication of cytotoxic treatment for primary tumors and autoimmune diseases. t-MNs result from a complex interaction between individual predisposition and exposition to toxic agents. Some different biological and clinical characteristics can be recognized according to the type of anticancer drug. Compared to de novo myeloid neoplasms, prognosis of t-MN is dismal. Age and karyotype are the most important prognostic factors for t-MN, which should be treated with frontline chemotherapy treatments that are appropriate for patients with myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) with similar disease characteristics. Allogeneic stem cell transplantation should be considered particularly for unfavorable karyotypes and younger patients with aggressive disease.

Fianchi, L., Criscuolo, M., Fabiani, E., Falconi, G., Maraglino, A. M. E., Voso, M. T., Pagano, L., Therapy-related myeloid neoplasms: Clinical perspectives, <<ONCOTARGETS AND THERAPY>>, 2018; 11 (11): 5909-5915. [doi:10.2147/OTT.S101333] [http://hdl.handle.net/10807/129585]

Therapy-related myeloid neoplasms: Clinical perspectives

Fianchi, Luana;Criscuolo, Marianna;Fabiani, Emiliano;Maraglino, Alessio Maria Edoardo;Voso, Maria Teresa;Pagano, Livio
2018

Abstract

Therapy-related myeloid neoplasms (t-MNs) are a complication of cytotoxic treatment for primary tumors and autoimmune diseases. t-MNs result from a complex interaction between individual predisposition and exposition to toxic agents. Some different biological and clinical characteristics can be recognized according to the type of anticancer drug. Compared to de novo myeloid neoplasms, prognosis of t-MN is dismal. Age and karyotype are the most important prognostic factors for t-MN, which should be treated with frontline chemotherapy treatments that are appropriate for patients with myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) with similar disease characteristics. Allogeneic stem cell transplantation should be considered particularly for unfavorable karyotypes and younger patients with aggressive disease.
Inglese
https://www.dovepress.com/getfile.php?fileID=44474
Fianchi, L., Criscuolo, M., Fabiani, E., Falconi, G., Maraglino, A. M. E., Voso, M. T., Pagano, L., Therapy-related myeloid neoplasms: Clinical perspectives, <>, 2018; 11 (11): 5909-5915. [doi:10.2147/OTT.S101333] [http://hdl.handle.net/10807/129585]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/129585
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact